April D. Kimmel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
April D. Kimmel has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Bassam Dahman
Department of Health Policy, Virginia Commonwealth University School of Public Health, Richmond, VA
11 shared publicationsZhongzhe Pan
Department of Health Policy, Virginia Commonwealth University School of Public Health, Richmond, VA
10 shared publicationsRose S. Bono
Department of Health Policy, Virginia Commonwealth University School of Public Health, Richmond, VA
9 shared publicationsDenis Nash
Institute for Implementation Science in Population Health City University of New York New York New York USA
5 shared publicationsGad Murenzi
School of Public Health, College of Medicine and Health Sciences University of Rwanda Kigali Rwanda
5 shared publicationsBenjamin Muhoza
School of Public Health, College of Medicine and Health Sciences University of Rwanda Kigali Rwanda
4 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Laboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Open AccessLaboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- 1 May 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (5) , 520-525
Brief Report: The Trials of Insurance-Based Data to Care-Rx: Low Enrollment in the Antiretroviral Improvement Among Medicaid EnrolleeS (AIMS) Study
Background: Approaches to strengthen Data-to-Care (D2C) models are needed. We tested an insurance-based D2C prescription model (D2C-Rx), which used antiretroviral therapy (ART) prescription claims to identify people with HIV who fail to fill ART prescriptions in a timely manner and to provide ART adherence support. The Antiretroviral Improvement among Medicaid EnrolleeS (AIMS) study was the first trial of an insurance-based D2C-Rx program. We describe AIMS study enrollment, focusing on patient-participants in the AIMS program arm. Setting: Virginia, United States. Methods: AIMS used Virginia Medicaid claims and HIV surveillance data to identify Medicaid enrollees with HIV who were without an ART prescription and their providers; study staff then provided targeted adherence support. The target patient-participant sample size was 1000. The outcome of interest was HIV viral suppression. Results: The study encountered difficulty recruiting patient-participants. Low enrollment prompted major changes to the protocol, including revisions to study design, eligibility criteria, and recruitment methods. These changes were unsuccessful. The trial was terminated because of low patient-participant enrollment (n = 4). Conclusions: Reasons for low patient-participant enrollment may include phone-based recruitment approach, lengthy identity verification and consent procedures, and lack of participant compensation. Although we aimed to identify people with HIV without a current ART prescription refill, several participants reported having their medications available; this discrepancy suggests issues with unexpected participant behavior (eg, stockpiling) or timeliness and accuracy of prescription claims data. Future insurance-based D2C-Rx interventions should account for these challenges, be tailored to context, and be nimble enough to pivot to alternative recruitment methods when needed.
- 1 May 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (5) , 520-525
Brief Report: The Trials of Insurance-Based Data to Care-Rx: Low Enrollment in the Antiretroviral Improvement Among Medicaid EnrolleeS (AIMS) Study
Background: Approaches to strengthen Data-to-Care (D2C) models are needed. We tested an insurance-based D2C prescription model (D2C-Rx), which used antiretroviral therapy (ART) prescription claims to identify people with HIV who fail to fill ART prescriptions in a timely manner and to provide ART adherence support. The Antiretroviral Improvement among Medicaid EnrolleeS (AIMS) study was the first trial of an insurance-based D2C-Rx program. We describe AIMS study enrollment, focusing on patient-participants in the AIMS program arm. Setting: Virginia, United States. Methods: AIMS used Virginia Medicaid claims and HIV surveillance data to identify Medicaid enrollees with HIV who were without an ART prescription and their providers; study staff then provided targeted adherence support. The target patient-participant sample size was 1000. The outcome of interest was HIV viral suppression. Results: The study encountered difficulty recruiting patient-participants. Low enrollment prompted major changes to the protocol, including revisions to study design, eligibility criteria, and recruitment methods. These changes were unsuccessful. The trial was terminated because of low patient-participant enrollment (n = 4). Conclusions: Reasons for low patient-participant enrollment may include phone-based recruitment approach, lengthy identity verification and consent procedures, and lack of participant compensation. Although we aimed to identify people with HIV without a current ART prescription refill, several participants reported having their medications available; this discrepancy suggests issues with unexpected participant behavior (eg, stockpiling) or timeliness and accuracy of prescription claims data. Future insurance-based D2C-Rx interventions should account for these challenges, be tailored to context, and be nimble enough to pivot to alternative recruitment methods when needed.
- Open Access
- 11 February 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (2) , e70078
Sustaining Rwanda's HIV response after elimination of PEPFAR funding: a modelling analysis of HIV epidemic and care continuum outcomes
Introduction: HIV prevention and treatment supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR) have saved millions of lives. Rwanda is among the most successful countries worldwide in achieving global targets with PEPFAR support. Abrupt PEPFAR funding uncertainty raises concerns about continued HIV epidemic control. We projected the impact of the Government of Rwanda's (GoR's) capacity to offset PEPFAR funding elimination on adult HIV epidemic and care continuum outcomes over 10 years. Methods: Using an HIV policy model calibrated to Rwanda, we assessed capacity to sustain HIV services at: 50% (with no capacity by GoR to cover the PEPFAR funding gap), 75%, 90% and 100% (with full capacity by GoR to cover the gap). Scenarios involved reducing the number on antiretroviral therapy (ART), immediately discontinuing ART and proportionally decreasing HIV diagnosis, ART initiation, and care re‐engagement. We projected epidemic outcomes (HIV prevalence, HIV incidence, number with HIV, new HIV infections, deaths) and care continuum outcomes (percentage diagnosed, percentage on ART among those diagnosed, percentage virally suppressed among those on ART). We calculated differences in projected outcomes for partial or no capacity versus full capacity. Secondary analyses assessed the timing of the GoR's response. Results: Compared to full capacity at 10 years, the model projected a 13.9%–38.7% increase in HIV prevalence and 69.0%–246.7% increase in HIV incidence across coverage capacity scenarios. This translated to 29,000–64,000 additional adults with HIV and 20,000–92,000 cumulative new adult HIV infections. Cumulative projected deaths increased by 10,000–51,200. The model projected continual reductions in percentage diagnosed at 10 years; percentage virally suppressed among those on ART was similar across scenarios. Higher, and more delayed, coverage capacity had projected outcomes similar to lower, and less delayed, coverage capacity. Outcomes for gradual increases in coverage capacity were generally similar to or better than full, but delayed, coverage capacity. Conclusions: Even in countries like Rwanda that have achieved epidemic control, abrupt and persistent elimination of PEPFAR funding could drastically reverse critical gains. Evidence quantifying the consequences of different capacities to sustain HIV services underscores the high stakes of rapid and sufficient action.
- 11 February 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (2) , e70078
Open AccessSustaining Rwanda's HIV response after elimination of PEPFAR funding: a modelling analysis of HIV epidemic and care continuum outcomes
Introduction: HIV prevention and treatment supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR) have saved millions of lives. Rwanda is among the most successful countries worldwide in achieving global targets with PEPFAR support. Abrupt PEPFAR funding uncertainty raises concerns about continued HIV epidemic control. We projected the impact of the Government of Rwanda's (GoR's) capacity to offset PEPFAR funding elimination on adult HIV epidemic and care continuum outcomes over 10 years. Methods: Using an HIV policy model calibrated to Rwanda, we assessed capacity to sustain HIV services at: 50% (with no capacity by GoR to cover the PEPFAR funding gap), 75%, 90% and 100% (with full capacity by GoR to cover the gap). Scenarios involved reducing the number on antiretroviral therapy (ART), immediately discontinuing ART and proportionally decreasing HIV diagnosis, ART initiation, and care re‐engagement. We projected epidemic outcomes (HIV prevalence, HIV incidence, number with HIV, new HIV infections, deaths) and care continuum outcomes (percentage diagnosed, percentage on ART among those diagnosed, percentage virally suppressed among those on ART). We calculated differences in projected outcomes for partial or no capacity versus full capacity. Secondary analyses assessed the timing of the GoR's response. Results: Compared to full capacity at 10 years, the model projected a 13.9%–38.7% increase in HIV prevalence and 69.0%–246.7% increase in HIV incidence across coverage capacity scenarios. This translated to 29,000–64,000 additional adults with HIV and 20,000–92,000 cumulative new adult HIV infections. Cumulative projected deaths increased by 10,000–51,200. The model projected continual reductions in percentage diagnosed at 10 years; percentage virally suppressed among those on ART was similar across scenarios. Higher, and more delayed, coverage capacity had projected outcomes similar to lower, and less delayed, coverage capacity. Outcomes for gradual increases in coverage capacity were generally similar to or better than full, but delayed, coverage capacity. Conclusions: Even in countries like Rwanda that have achieved epidemic control, abrupt and persistent elimination of PEPFAR funding could drastically reverse critical gains. Evidence quantifying the consequences of different capacities to sustain HIV services underscores the high stakes of rapid and sufficient action.
- Open Access
Limited user fees for adult HIV diagnosis and routine laboratory monitoring in the global IeDEA consortium: analysis in 42 countries
ASBSTRACT: Introduction: While HIV services have scaled up dramatically under universal treatment recommendations, availability of routine laboratory services for HIV diagnosis and management, and the extent to which user fees are charged for these services, are not well documented. We described site-level availability and user fees for adult HIV laboratory testing among 238 sites in 42 countries of the International epidemiology Databases to Evaluate AIDS (IeDEA) global consortium, and contextualized practices by site- and country-level characteristics, including country income level and receipt of Global Fund or PEPFAR support. Methods: Availability of HIV-related laboratory services and charging of user fees, were examined via an IeDEA site assessment survey conducted September 2020–March 2021, with responses reflecting practices in 2019. Laboratory services examined included: HIV-1/HIV-2 antigen/antibody immunoassay test (HIV-1/2 Ag/Ab), HIV-1 p24 antigen test (p24), supplemental HIV-1/HIV-2 antibody differentiation immunoassay (HIV-1/2 Ab suppl), quantitative PCR for HIV viral load (VL), HIV-1 genotypic drug resistance testing (genotyping), and CD4 count testing (CD4). Availability was defined as provided on-site in the HIV clinic or within the same health facility. User fees were fees other than insurance co-pays paid for a given test, conditional on their on-site availability. We reported frequencies and percentages of site-level availability and user fees, overall and by site- and country-level characteristics. Results: Most sites (88%) reported HIV-1/HIV-2 Ag/Ab availability on-site, while fewer than half of sites reported having p24 and HIV-1/2 Ab suppl available. Approximately half of sites reported VL and CD4 testing availability, while less than one-third of sites (28%) reported genotyping availability. The percentage of sites reporting user fees ranged from 6.5% (HIV-1/2 Ag/Ab) to 10.5% (CD4). A higher percentage of sites reporting user fees were from upper-middle income countries, countries receiving any Global Fund or any PEPFAR country support, and the Asia-Pacific region. Conclusions: While most HIV care sites participating in IeDEA did not charge user fees for HIV-related laboratory tests in 2019, on-site availability of such tests was limited. Continued action to identify and address constraints in the routine provision of these laboratory services is critical for appropriate management of HIV.
Open AccessLimited user fees for adult HIV diagnosis and routine laboratory monitoring in the global IeDEA consortium: analysis in 42 countries
ASBSTRACT: Introduction: While HIV services have scaled up dramatically under universal treatment recommendations, availability of routine laboratory services for HIV diagnosis and management, and the extent to which user fees are charged for these services, are not well documented. We described site-level availability and user fees for adult HIV laboratory testing among 238 sites in 42 countries of the International epidemiology Databases to Evaluate AIDS (IeDEA) global consortium, and contextualized practices by site- and country-level characteristics, including country income level and receipt of Global Fund or PEPFAR support. Methods: Availability of HIV-related laboratory services and charging of user fees, were examined via an IeDEA site assessment survey conducted September 2020–March 2021, with responses reflecting practices in 2019. Laboratory services examined included: HIV-1/HIV-2 antigen/antibody immunoassay test (HIV-1/2 Ag/Ab), HIV-1 p24 antigen test (p24), supplemental HIV-1/HIV-2 antibody differentiation immunoassay (HIV-1/2 Ab suppl), quantitative PCR for HIV viral load (VL), HIV-1 genotypic drug resistance testing (genotyping), and CD4 count testing (CD4). Availability was defined as provided on-site in the HIV clinic or within the same health facility. User fees were fees other than insurance co-pays paid for a given test, conditional on their on-site availability. We reported frequencies and percentages of site-level availability and user fees, overall and by site- and country-level characteristics. Results: Most sites (88%) reported HIV-1/HIV-2 Ag/Ab availability on-site, while fewer than half of sites reported having p24 and HIV-1/2 Ab suppl available. Approximately half of sites reported VL and CD4 testing availability, while less than one-third of sites (28%) reported genotyping availability. The percentage of sites reporting user fees ranged from 6.5% (HIV-1/2 Ag/Ab) to 10.5% (CD4). A higher percentage of sites reporting user fees were from upper-middle income countries, countries receiving any Global Fund or any PEPFAR country support, and the Asia-Pacific region. Conclusions: While most HIV care sites participating in IeDEA did not charge user fees for HIV-related laboratory tests in 2019, on-site availability of such tests was limited. Continued action to identify and address constraints in the routine provision of these laboratory services is critical for appropriate management of HIV.
- 24 November 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 32 (2) , E64-E68
RVA Breathes: Costs of a System of Community-Based Interventions to Improve Asthma Care
Pediatric asthma disparities persist. In a randomized, controlled trial (2017-2022), the Richmond, Virginia (RVA) Breathes program, which was a series of community-based asthma interventions, was tested in a sample of 250 children (5-11 years; 78% African American/Black). Results suggested reduced asthma-related hospitalizations for the full intervention arm (asthma education, home environment remediation, and school intervention). Leveraging detailed costs from program expense reports, this study analyzed the costs of the RVA Breathes full intervention. Five-year costs of the full intervention were $1 922 514 (on average $3314 annually per participating household). Personnel costs contributed the largest share (74.8%), followed by overhead costs (18.9%). Costs for follow-up, outreach staff, and academic leadership were key cost drivers. When restricting these cost drivers collectively, as in a public health implementation approach, average annual costs per participating household decreased by 45.0%. In practice, streamlining the implementation of the RVA Breathes full intervention could improve program affordability.
- 24 November 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 32 (2) , E64-E68
RVA Breathes: Costs of a System of Community-Based Interventions to Improve Asthma Care
Pediatric asthma disparities persist. In a randomized, controlled trial (2017-2022), the Richmond, Virginia (RVA) Breathes program, which was a series of community-based asthma interventions, was tested in a sample of 250 children (5-11 years; 78% African American/Black). Results suggested reduced asthma-related hospitalizations for the full intervention arm (asthma education, home environment remediation, and school intervention). Leveraging detailed costs from program expense reports, this study analyzed the costs of the RVA Breathes full intervention. Five-year costs of the full intervention were $1 922 514 (on average $3314 annually per participating household). Personnel costs contributed the largest share (74.8%), followed by overhead costs (18.9%). Costs for follow-up, outreach staff, and academic leadership were key cost drivers. When restricting these cost drivers collectively, as in a public health implementation approach, average annual costs per participating household decreased by 45.0%. In practice, streamlining the implementation of the RVA Breathes full intervention could improve program affordability.
- Open Access
- 31 May 2025
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 48 (11) , 704-715
Follow-Up Time of Anal Cancer Screening among Women Living with HIV at High Risk of Developing Anal Cancer
Introduction: Screening for anal cancer can help in its secondary prevention. We examined follow-up time for anal cancer screening among high-risk women living with HIV (WLHIV) and whether it varies with the number of risk factors for developing anal cancer. Methods: A retrospective cohort study involving high-risk WLHIV under 65 enrolled in Medicaid for at least 2 years across 16 US states plus D.C. from 2009 to 2012. High risk was defined by a history of abnormal cervical test results or genital warts. Initial anal cancer screening was the first screening after a high-risk diagnosis, with results classified as normal or abnormal. Follow-up was until the next screening. Follow-up time was analyzed using the Kaplan-Meier estimator and the Cox Proportional Hazards model. Results: Our cohort included 4,340 high-risk WLHIV, mean (±SD) age 41.8 (±10.2) years. About 18% (763/4,340) had both risk factors, while 9% (374/4,340) had abnormal results on their initial anal cancer screening. The median time, or the time at which 50% of the cohort received follow-up screening, was 17.53 (95% CI = 16.13, 18.30) months overall. Follow-up screening was more common in women with both risk factors for developing anal cancer compared to those with one risk factor (median time: 10.13 [95% CI = 8.90, 11.47] vs. 19.56 [95% CI = 18.36, 21.40] months; adjusted hazard ratio [aHR] = 1.53 [95% CI = 1.38, 1.68]). The follow-up was also more common in women with abnormal results on the initial screening compared to those with a normal result (median time: 7.00 [95% CI = 5.40, 9.23] vs. 18.91 [95% CI = 17.92, 20.12] months; aHR = 2.00 [95% CI = 1.76, 2.28]). Conclusion: Follow-up time for anal cancer screening in high-risk WLHIV was about 1.5 years but varied according to the risk of developing anal cancer. Future research should examine the guideline-concordance of follow-up screening time given the recently issued guidelines for anal cancer screening.
- 31 May 2025
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 48 (11) , 704-715
Open AccessFollow-Up Time of Anal Cancer Screening among Women Living with HIV at High Risk of Developing Anal Cancer
Introduction: Screening for anal cancer can help in its secondary prevention. We examined follow-up time for anal cancer screening among high-risk women living with HIV (WLHIV) and whether it varies with the number of risk factors for developing anal cancer. Methods: A retrospective cohort study involving high-risk WLHIV under 65 enrolled in Medicaid for at least 2 years across 16 US states plus D.C. from 2009 to 2012. High risk was defined by a history of abnormal cervical test results or genital warts. Initial anal cancer screening was the first screening after a high-risk diagnosis, with results classified as normal or abnormal. Follow-up was until the next screening. Follow-up time was analyzed using the Kaplan-Meier estimator and the Cox Proportional Hazards model. Results: Our cohort included 4,340 high-risk WLHIV, mean (±SD) age 41.8 (±10.2) years. About 18% (763/4,340) had both risk factors, while 9% (374/4,340) had abnormal results on their initial anal cancer screening. The median time, or the time at which 50% of the cohort received follow-up screening, was 17.53 (95% CI = 16.13, 18.30) months overall. Follow-up screening was more common in women with both risk factors for developing anal cancer compared to those with one risk factor (median time: 10.13 [95% CI = 8.90, 11.47] vs. 19.56 [95% CI = 18.36, 21.40] months; adjusted hazard ratio [aHR] = 1.53 [95% CI = 1.38, 1.68]). The follow-up was also more common in women with abnormal results on the initial screening compared to those with a normal result (median time: 7.00 [95% CI = 5.40, 9.23] vs. 18.91 [95% CI = 17.92, 20.12] months; aHR = 2.00 [95% CI = 1.76, 2.28]). Conclusion: Follow-up time for anal cancer screening in high-risk WLHIV was about 1.5 years but varied according to the risk of developing anal cancer. Future research should examine the guideline-concordance of follow-up screening time given the recently issued guidelines for anal cancer screening.
- Open Access
- 14 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0310662
Development and calibration of a mathematical model of HIV outcomes among Rwandan adults: Informing achievement of global targets across sub-populations in Rwanda
Background: We developed and calibrated the Central Africa-International epidemiology Databases to Evaluate AIDS (CA-IeDEA) HIV policy model to inform achievement of global goals, overall and across all sub-populations, in Rwanda. Methods: We created a deterministic dynamic model to project adult HIV epidemic and care continuum outcomes, overall and for 35 subpopulations (age group, sex, HIV acquisition risk, urbanicity). Data came from the Rwanda cohort of CA-IeDEA, 2004–2020; Rwanda Demographic and Health Surveys, 2005, 2010, 2015; Rwanda Population-based HIV Impact Assessment, 2019; and literature and reports. We calibrated the model to 47 targets by selecting 50 best-fitting parameter sets. Targets reflected epidemic, global goals and other indicators. Best-fitting sets minimized the summed absolute value of the percentage deviation (AVPD) between projections and targets. Good performance was mean AVPD ≤5% across best-fitting sets and/or projections within target confidence intervals; acceptable was mean AVPD >5%–15%. Results: Across indicators, 1,843 of 2,350 (78.4%) model projections were a good or acceptable fit to calibration targets. For HIV epidemic indicators, 247 of 300 (82.3%) projections were a good fit to targets, with the model performing better for women (80.3% a good fit) than for men (62.3% a good fit). For global goals indicators, 97 of 100 (97.0%) projections were a good fit; model performance was similar for women and men. For other indicators, 708 of 950 (74.5%) projections were a good or acceptable fit. Fit was better for women than for men (percentage virally suppressed only) and when restricting targets for number on ART to 2013 and beyond. Conclusions: The CA-IeDEA HIV policy model fits historical data and can inform policy solutions for achieving global goals across all sub-populations in Rwanda. High-quality population-based data and novel approaches that account for calibration target quality are critical to ongoing use of mathematical models for programmatic planning.
- 14 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0310662
Open AccessDevelopment and calibration of a mathematical model of HIV outcomes among Rwandan adults: Informing achievement of global targets across sub-populations in Rwanda
Background: We developed and calibrated the Central Africa-International epidemiology Databases to Evaluate AIDS (CA-IeDEA) HIV policy model to inform achievement of global goals, overall and across all sub-populations, in Rwanda. Methods: We created a deterministic dynamic model to project adult HIV epidemic and care continuum outcomes, overall and for 35 subpopulations (age group, sex, HIV acquisition risk, urbanicity). Data came from the Rwanda cohort of CA-IeDEA, 2004–2020; Rwanda Demographic and Health Surveys, 2005, 2010, 2015; Rwanda Population-based HIV Impact Assessment, 2019; and literature and reports. We calibrated the model to 47 targets by selecting 50 best-fitting parameter sets. Targets reflected epidemic, global goals and other indicators. Best-fitting sets minimized the summed absolute value of the percentage deviation (AVPD) between projections and targets. Good performance was mean AVPD ≤5% across best-fitting sets and/or projections within target confidence intervals; acceptable was mean AVPD >5%–15%. Results: Across indicators, 1,843 of 2,350 (78.4%) model projections were a good or acceptable fit to calibration targets. For HIV epidemic indicators, 247 of 300 (82.3%) projections were a good fit to targets, with the model performing better for women (80.3% a good fit) than for men (62.3% a good fit). For global goals indicators, 97 of 100 (97.0%) projections were a good fit; model performance was similar for women and men. For other indicators, 708 of 950 (74.5%) projections were a good or acceptable fit. Fit was better for women than for men (percentage virally suppressed only) and when restricting targets for number on ART to 2013 and beyond. Conclusions: The CA-IeDEA HIV policy model fits historical data and can inform policy solutions for achieving global goals across all sub-populations in Rwanda. High-quality population-based data and novel approaches that account for calibration target quality are critical to ongoing use of mathematical models for programmatic planning.
- Open Access
Sustaining Rwanda’s HIV response after elimination of PEPFAR funding: a modeling analysis
Introduction: HIV prevention and treatment supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) have saved millions of lives. Rwanda is among the most successful countries around the world in achieving global targets with PEPFAR support. However, abrupt funding uncertainty around PEPFAR raises concerns about continued HIV epidemic control. We projected the impact of the Government of Rwanda’s (GoR’s) capacity to offset the elimination of PEPFAR funding on adult HIV epidemic and care continuum outcomes over 10 years. Methods: Using an HIV policy model calibrated to Rwanda, we assessed: capacity to sustain HIV services at 50% (with no capacity by GoR to cover the PEPFAR funding gap), 75%, 90%, and 100% (with full capacity by GoR to cover the PEPFAR funding gap). Scenarios were operationalized by reducing the number on antiretroviral therapy (ART), with immediate ART discontinuation and proportional decreases in HIV diagnosis, ART initiation, and care re- engagement. We projected HIV epidemic outcomes (HIV prevalence, HIV incidence, number with HIV, new HIV infections, deaths) and care continuum outcomes (percent diagnosed, percent on ART among those diagnosed, percent virally suppressed among those on ART). We calculated differences in projected outcomes for partial or no capacity versus full capacity. Secondary analyses assessed delayed coverage capacity by 1 and 3 years. Results: Compared to full capacity at 10 years, the model projected a 13.9%–38.7% increase in HIV prevalence and 69.0%–246.7% increase in HIV incidence across coverage capacity scenarios. This translated to 29,000–64,000 additional adults with HIV and 20,000–92,000 cumulative new adult HIV infections. Cumulative projected deaths increased by 10,000–51,200. The model projected continual reductions in percent diagnosed at 10 years; percent virally suppressed among those on ART was similar across scenarios. Higher, and more delayed, coverage capacity had projected outcomes similar to lower, and less delayed, coverage capacity. Conclusions: Even in countries like Rwanda that have achieved epidemic control, abrupt and persistent elimination of PEPFAR funding could drastically reverse critical gains. Evidence quantifying the consequences of different capacities to sustain HIV services underscores the high stakes of rapid and sufficient action.
Open AccessSustaining Rwanda’s HIV response after elimination of PEPFAR funding: a modeling analysis
Introduction: HIV prevention and treatment supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) have saved millions of lives. Rwanda is among the most successful countries around the world in achieving global targets with PEPFAR support. However, abrupt funding uncertainty around PEPFAR raises concerns about continued HIV epidemic control. We projected the impact of the Government of Rwanda’s (GoR’s) capacity to offset the elimination of PEPFAR funding on adult HIV epidemic and care continuum outcomes over 10 years. Methods: Using an HIV policy model calibrated to Rwanda, we assessed: capacity to sustain HIV services at 50% (with no capacity by GoR to cover the PEPFAR funding gap), 75%, 90%, and 100% (with full capacity by GoR to cover the PEPFAR funding gap). Scenarios were operationalized by reducing the number on antiretroviral therapy (ART), with immediate ART discontinuation and proportional decreases in HIV diagnosis, ART initiation, and care re- engagement. We projected HIV epidemic outcomes (HIV prevalence, HIV incidence, number with HIV, new HIV infections, deaths) and care continuum outcomes (percent diagnosed, percent on ART among those diagnosed, percent virally suppressed among those on ART). We calculated differences in projected outcomes for partial or no capacity versus full capacity. Secondary analyses assessed delayed coverage capacity by 1 and 3 years. Results: Compared to full capacity at 10 years, the model projected a 13.9%–38.7% increase in HIV prevalence and 69.0%–246.7% increase in HIV incidence across coverage capacity scenarios. This translated to 29,000–64,000 additional adults with HIV and 20,000–92,000 cumulative new adult HIV infections. Cumulative projected deaths increased by 10,000–51,200. The model projected continual reductions in percent diagnosed at 10 years; percent virally suppressed among those on ART was similar across scenarios. Higher, and more delayed, coverage capacity had projected outcomes similar to lower, and less delayed, coverage capacity. Conclusions: Even in countries like Rwanda that have achieved epidemic control, abrupt and persistent elimination of PEPFAR funding could drastically reverse critical gains. Evidence quantifying the consequences of different capacities to sustain HIV services underscores the high stakes of rapid and sufficient action.
- Open Access
- 18 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Limited preventive care among Medicaid enrollees with HIV in the US South
Routine preventive care (RPC) services are recommended for people with HIV, who have higher risk of certain preventable conditions. We used a pooled cross-section of patient-years to examine receipt of 5 annual RPC services among Medicaid enrollees in the US South. Data were person-level administrative claims (Medicaid Analytic eXtract, 2008–2012) and county-level characteristics for 16 Southern states plus District of Columbia. Generalized estimating equations estimated the probability of lipid, glucose, syphilis, and cervical cancer (women only) screenings and influenza vaccination. We also examined service receipt among subgroups including enrollees requiring more general or HIV-specific care, in managed care, < 45 years and, separately, Non-Hispanic Black and Non-Hispanic White enrollees. The sample included 57,695 adult Medicaid enrollees with HIV (187,275 enrollee-years) that were majority 45–54 years (38.0%), female (53.6%), Non-Hispanic Black (54.3%), and urban (90.2%). Enrollees received lipid, syphilis, and cervical cancer screenings and influenza vaccination in < 50% and glucose screening in 71.7% of total enrollment-years. The adjusted probability was low (< 50%) for all services except glucose screening (estimated probability 81%; 95% confidence interval 78%, 83%). Findings were similar across subgroups. There is consistent, suboptimal receipt of RPC services among people with HIV. Approaches are needed to increase uptake of RPC services.
- 18 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessLimited preventive care among Medicaid enrollees with HIV in the US South
Routine preventive care (RPC) services are recommended for people with HIV, who have higher risk of certain preventable conditions. We used a pooled cross-section of patient-years to examine receipt of 5 annual RPC services among Medicaid enrollees in the US South. Data were person-level administrative claims (Medicaid Analytic eXtract, 2008–2012) and county-level characteristics for 16 Southern states plus District of Columbia. Generalized estimating equations estimated the probability of lipid, glucose, syphilis, and cervical cancer (women only) screenings and influenza vaccination. We also examined service receipt among subgroups including enrollees requiring more general or HIV-specific care, in managed care, < 45 years and, separately, Non-Hispanic Black and Non-Hispanic White enrollees. The sample included 57,695 adult Medicaid enrollees with HIV (187,275 enrollee-years) that were majority 45–54 years (38.0%), female (53.6%), Non-Hispanic Black (54.3%), and urban (90.2%). Enrollees received lipid, syphilis, and cervical cancer screenings and influenza vaccination in < 50% and glucose screening in 71.7% of total enrollment-years. The adjusted probability was low (< 50%) for all services except glucose screening (estimated probability 81%; 95% confidence interval 78%, 83%). Findings were similar across subgroups. There is consistent, suboptimal receipt of RPC services among people with HIV. Approaches are needed to increase uptake of RPC services.